Cytori is committed to developing and commercializing specialty therapeutics.
Since 2002, Cytori has enabled researchers and clinicians to study and administer cell therapies using our novel Celution® System platform which harnesses the potential of stem and regenerative cells from adipose tissue.
In 2017, Cytori strengthened its specialty therapeutics position by acquiring a nanomedicine platform technology that combines widely-known and prescribed chemotherapy agents, doxorubicin and docetaxel, both with liposomal encapsulation technology.
This marriage of technologies has the potential to improve patient care for both life-debilitating and life-threatening conditions and diseases. .
Cytori Therapeutics, Inc. is dedicated to enhancing lives through the development of novel therapeutics. To realize this mission, Cytori defines, develops, and delivers specialty therapeutics that address poorly met market and medical needs. Through constantly balancing a blend of creativity, rigor, focused energy, and agility, we strive to deliver meaningful results that create exceptional value for patients, customers, partners, employees, shareholders, and society.
- We do what is right, deliver what we promise and own the outcome.
- We place our patients and customers at the heart of everything we do.
- We thoughtfully balance competing priorities to achieve important results.
- We are an agile company that embraces big challenges.
- We value spirited communication and care about one another.
Marc H. Hedrick, M.D.
President & CEO
Dr. Marc H. Hedrick was appointed President in May 2004 and CEO in 2014. Dr. Hedrick joined Cytori Therapeutics as Chief Scientific Officer, Medical Director and Director in October 2002. Previously, Dr. Hedrick co-founded, and served as President and Chief Executive Officer of StemSource, Inc., a company specializing in stem cell research and development. Dr. Hedrick, a general, vascular & plastic surgeon, is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, Dr. Hedrick directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick obtained his M.D. from the University of Texas Southwestern Medical School, Dallas and an M.B.A from UCLA in 2005.
Tiago M. Girão
Vice President of Finance & Chief Financial Officer
Mr. Tiago Girão was appointed Vice President of Finance and Chief Financial Officer (CFO) in September 2014. Mr. Girão joins Cytori Therapeutics from NuVasive, Inc. where he recently served as International Controller. Prior to his International Controller role, he served as Director, Financial Reporting, where he managed a team responsible for all corporate technical accounting and SEC related matters. Prior to joining NuVasive, Mr. Girão served as Senior Manager, Assurance at KPMG, Cytori’s independent audit firm and was responsible for Cytori’s account for six years. Prior to joining KPMG, Mr. Girão was a senior accountant for Ernst & Young in Brazil. Mr. Girão is a certified public accountant with 14 years experience in the accounting, finance and reporting for U.S. public companies and substantial experience in global finance and operations.
Kenneth K. Kleinhenz
Vice President, Global Regulatory Affairs
Kenneth K. Kleinhenz was appointed Vice President, Global Regulatory Affairs in April 2013. Previously, he had served as our Vice President of Regulatory Affairs & Quality Assurance since November 2007 and as Director of Regulatory Affairs since joining us in 1999. From September 1998 to June 1999, Mr. Kleinhenz was the Technical Director of IFM Manufacturing. He served as a Chief Microbiologist for Becton Dickinson from June 1997 to September 1998, and as Manager of Quality Assurance and Regulatory Affairs at Pacific Pharmaceuticals from September 1993 to June 1997. Mr. Kleinhenz is a veteran of the United States Navy, where he served as a Clinical Microbiologist for six years at the Naval Hospital, San Diego. He earned his B.S. in Microbiology at the University of California, San Diego (UCSD) and his M.B.A. in Technology Management at the University of Phoenix.
John K. Fraser, PhD
Dr. John Fraser is the Chief Scientist at Cytori Therapeutics Inc. Prior to joining Cytori, Dr. Fraser had a 12 year career in the Department of Medicine at UCLA. Before joining Cytori, he was the Director and Principal Investigator of the UCLA Umbilical Cord Blood Bank, a NIH-funded allogeneic cord blood stem cell bank. Dr Fraser has a PhD from the University of Otago in New Zealand and a Bachelor of Science degree (Biochemistry and Physiology) from Victoria University of Wellington. He has published more than 40 peer-reviewed papers, has 12 patents issued in the USA. He has published more than 55 peer-reviewed papers and has 22 patents issued in the USA. During his 30 year career in cell therapy he has been awarded more than $30 million in research contract and grant funding from the US government.
General Counsel & VP Business Development
Mr. Jeremy Hayden serves as our General Counsel and Vice President of Business Development, positions he has held since July 2015. Mr. Hayden joined Cytori from Volcano Corporation, where he served as Assistant General Counsel. Prior to his tenure at Volcano, Mr. Hayden practiced corporate and securities law at several international law firms, including McKenna Long & Aldridge, LLP and Mintz Levin Cohn Ferris Glovsky & Popeo, P.C. Mr. Hayden received his A.B. in Politics from Princeton University and his J.D. from the University of Michigan Law School.
Vice President & General Manager of Cell Therapy
Joining Cytori Therapeutics in October of 2015, John D. Harris serves as the Vice President & General Manager of Cell Therapy. Mr. Harris has 20+ years experience in medical device and biotechnology, most recently serving as the Vice President and General Manager of Becton Dickinson’s operations in Japan. Prior to BD, Mr. Harris held Business Development, Product Development, Marketing and Sales leadership roles with Tyco Electronics, Delphi, Sorenson Medical, Kimberly-Clark Healthcare and Ballard Medical Products. Mr. Harris is a member of the Board of Governors of the American Chamber of Commerce in Japan (ACCJ) and a member of the Executive Committee of the American Medical Device & Diagnostics Association (AMDD), where he chairs the Regenerative Medicine Working Group. Mr. Harris holds Master of Business Administration (MBA) and Bachelor of Arts (BA) degrees from University of Utah.
Vice President, Portfolio Management and Development
Cheri Rice was appointed Vice President, Portfolio Management and Development at Cytori Therapeutics, Inc. in August of 2015. Prior to joining Cytori, she served as Vice President of Disposable Development for Volcano Corporation, a leading developer of intravascular ultrasound diagnostic equipment from June 2008 until May 2015. Prior to Volcano she worked her way up through the ranks at Abbott Vascular, ending her tenure as Manager of Process Development. She brings 27 years of Program Management and Engineering in experience to Cytori. Cheri has her bachelor’s degree in Mechanical Engineering from San Diego State University.
Vice President, Global Marketing
Russ Havranek serves as Vice President, Global Marketing and joined Cytori in 2014. Mr. Havranek has 20 years of marketing, general management, and product development experience with major life science companies including CareFusion Corporation, Volcano Corporation, Guidant Corporation, and Johnson & Johnson. Mr. Havranek received a M.B.A. in Marketing from the University of California, Berkeley, a M.S. in Bioengineering from Clemson University, and a B.S. in Biomedical Engineering from Northwestern University.
Mark T. Marino, M.D.
Senior Vice President & Chief Medical Officer
Mark Marino joined Cytori as Senior Vice President, Clinical Affairs in May 2016 and then became Chief Medical Officer in August 2016. Previously, he served as Vice President and head of Internal Medicine Development group at Daiichi-Sankyo. Prior to Daiichi-Sankyo, he was with MannKind Corporation holding positions of Senior Vice President of Research, Exploratory Medicine and Clinical Operations. Prior to that, he was Global head of Clinical Pharmacology at both Eisai and Roche. He was the head of Pharmacology at the Walter Reed Army Institute of Research as well as Associate Professor of Medicine at the Uniformed Services University of the Health Sciences and a staff physician at the Walter Reed Army Medical Center. Dr. Marino received his medical degree from the Albert Einstein School of Medicine and his specialty training in internal medicine at the Eisenhower Army Medical Center and sub-specialty training in Clinical Pharmacology at the Uniformed Services University of the Health Sciences.
David M. Rickey
David M. Rickey has served as a Director of the Company since November 1999 and was appointed Chairman in June 2013. Mr. Rickey was President and Chief Executive Officer of Applied Micro Circuits Corporation (AMCC) from February 1996 to March 2005. Mr. Rickey served on the Board of Directors of AMCC from February 1996 to March 2005, and as its Chairman of the Board from August 2000 to March 2005. Mr. Rickey also served as a Director of AMI Semiconductor, Inc. from 2000 to 2006 and was a Director of Netlist, Inc. from 2005 to 2008, as well as several private technology companies. He holds a B.S. from Marietta College, a B.S. from Columbia University and an M.S. from Stanford University.
Richard J. Hawkins
Richard J. Hawkins joined us as Director in December 2007. Mr. Hawkins is currently the CEO of Lumos Pharma, Inc., a start-up pharma company. Mr. Hawkins founded LabNow Inc., a diagnostic device company developing rapid, point-of-care, physician office-based diagnostic testing systems, and served Chairman and CEO from 2004 until October 2009. Mr. Hawkins previously founded and guided the growth of Pharmaco, a clinical drug development services company where he served as Chairman, President, and Chief Executive Officer. He is a founder of id2, a pharmaceutical and biotechnology research management company, Sensus Drug Development Corp., a biotechnology company that was sold to Pfizer, and Covance Biotechnology Services, and served as Chairman of the Board for LoopOne, Inc., a shipping and logistics software company. Mr. Hawkins holds a B.S. in biology from Ohio University.
Paul W. Hawran
Paul W. Hawran joined Cytori Therapeutics as Director in February 2005. Mr. Hawran is the founder of and currently serves as President and CEO of Ascendant MDx, a molecular diagnostic testing company. Previously, he served as Chief Financial Officer of Sequenom, Inc., from April 2007 to September 2000 and served on their Board of Directors from August 2006 to February 2007. He previously served as Executive Vice President and Chief Financial Officer of Neurocrine Biosciences, Inc. from May 1993 through September 2006. Mr. Hawran has also held executive management positions at SmithKline Beecham (now Glaxo SmithKline), most recently as Vice President and Treasurer. Prior to joining SmithKline (Beecham) in 1984, he held various financial positions at Warner Communications (now Time Warner) involving corporate finance, financial planning and domestic and international budgeting and forecasting. Mr. Hawran received a B.S. in finance from St. John’s University and an M.S. in taxation from Seton Hall University. He is a certified public accountant and a member of the American Institute of Certified Public Accountants.
Gary A. Lyons
Gary A. Lyons joined Cytori as a Director in October 2013. Mr. Lyons has served on the Board of Directors of Neurocrine Biosciences since 1993 and as the President and Chief Executive Officer of Neurocrine from 1993 through January 2008. Prior to joining Neurocrine Biosciences, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development and Vice President of Sales. Mr. Lyons currently serves on the Boards of Directors for Rigel Pharmaceuticals, Inc., Vical Incorporated, and KaloBios Pharmaceuticals, Inc. Mr. Lyons was previously a director of PDL BioPharma, Inc., Poniard Pharmaceuticals, Inc., Neurogesx and Facet Biotech Corporation. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management.
Gail K. Naughton
Gail K. Naughton, PhD joined Cytori Therapeutics’ Board of Directors as a director in July 2014. Dr. Naughton was the co-founder and co-inventor of the technology at Advanced Tissue Sciences where she held key management positions for more than 15 years, including President, Chief Operating Officer and Director. She also served as the Dean of the College of Business Administration at San Diego State University for nine years. Currently, Dr. Naughton serves as the Chief Executive Officer and the Chairman of the Board of Histogen, a regenerative medicine company she founded in 2007. Dr. Naughton also currently serves on the Board of Directors for CR Bard, Inc. Dr. Naughton holds a B.S. in Biology from St. Francis College as well as a Master’s in Histology and a PhD in cell biology from New York University Medical Center. She also holds an EMBA from the Anderson School at the University of California, Los Angeles.
Marc H. Hedrick
President & CEO
Dr. Marc H. Hedrick was appointed President in May 2004 and as CEO in 2014. Dr. Hedrick joined Cytori Therapeutics as Chief Scientific Officer, Medical Director and Director in October 2002. Previously, Dr. Hedrick co-founded, and served as President and Chief Executive Officer of StemSource, Inc., a company specializing in stem cell research and development. Dr. Hedrick, a general, vascular & plastic surgeon, is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, Dr. Hedrick directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick obtained his M.D. from the University of Texas Southwestern Medical School, Dallas and an M.B.A from UCLA in 2005.
Ronald A. Martell
Ronald A. Martell joined our Board in December 2016. Mr. Martell has more than 25 years’ experience building and managing unique businesses in the biotech industry, and most recently served as Executive Chairman of KaloBios and as Chief Executive Officer at Sevion Therapeutics, prior to which he held similar roles at NeurogesX and at Poniard Pharmaceuticals. Earlier in his career Mr. Martell served as Senior Vice President of Commercial Operations at ImClone Systems, where he built ImClone Systems’ worldwide commercial operations and field sales force to market and commercialize Erbitux® with partners Bristol-Myers Squibb and Merck KGaA. Prior to joining ImClone Systems, Mr. Martell worked for more than 10 years at Genentech in a variety of leadership positions, the last of which was Group Manager, Oncology. At Genentech, he was responsible for building the company’s oncology franchise including the launch of Herceptin® for metastatic HER-2 positive breast cancer and Rituxan® for non-Hodgkin’s lymphoma.